Jinxin Group Successfully Introduces High-quality International Investors, Capital Group Private Markets and GL Capital


Close Cooperation of Industry Leader and Global Investors
Accelerates the Pace of Corporate Development

HONG KONG – (ACN Newswire) – Chengdu Jinxin Healthcare Investment Management Group (“Jinxin Group” or the “Group”), a Sichuan-based international healthcare group, is pleased to announce that the ceremony for the completion of investments in JINXIN Medical Investment Group Limited (“JINXIN Healthcare”), the holding company of the maternity and psychiatry services segment under the Group, by Funds managed by Capital Group Private Markets (CGPM) and GL Capital, was held at Sichuan Jinxin Women & Children Hospital on 8 June 2018. Provincial and city leaders, including Mr. Peng Jie, Associate Counsel of the Health and Family Planning Commission of Sichuan Province, Mr. Wang Gian, District Mayor of Jinjiang District People’s Government and Mr. Zhang Yi, Associate Counsel of the Health and Family Planning Commission of Chengdu, attended the ceremony and witnessed another successful introduction of leading global investors by the Jinxin Group, which was a firm step towards the completion of the Group’s global strategic layout.

This investment was led by CGPM, part of the U.S.-based Capital Group Companies. Founded in 1931, Capital Group Companies is one of the world’s largest and most successful investment organizations and manages approximately US$1.7 trillion investment assets globally. GL Capital is a leading Greater China healthcare-focused, value-driven investment management group. Established in 2010 by the former Country President of Novartis China, Mr. Jeffrey Li, it manages various USD and RMB funds and has invested in over 40 companies as of the end of 2017. About 29% of the total shares of JINXIN Healthcare will be transferred to CGPM and GL Capital.

Jinxin Group, the predecessor of which was established in [1951], operates business lines in maternity and psychiatry services, in-vitro fertility (IVF) services and elderly care, with a goal to create synergies among them and meet China’s growing healthcare demand. Its subsidiary, JINXIN Healthcare is one of the largest obstetrics and gynecology hospital chains in Sichuan Province which has a population of 87 million. In 2017 it completed about 20,000 maternity deliveries. JINXIN Healthcare’s flagship hospital, Sichuan Jinxin Women’s and Children’s Hospital is Asia’s largest single-specialty hospital that has passed the international JCI accreditation and focuses on serving the growing mid- and high-end market segments with its top-notch team of medical experts, advanced clinical technologies and equipment, and state-of-art hospital facility.

Chairman of Jinxin Group said, “As a leading private healthcare enterprise in China, Jinxin Group always strives to enhance our overall competitiveness. The introduction of these two high-quality institutional investors into JINXIN Healthcare demonstrates their recognition of the business segment’s market leadership and value, as well as achieves for us institutionalization and diversification of the shareholder base. They will help us further raise the governance standards and gain access to the capital market. We believe they can also bring valuable global industry resources and expertise to our close partnership.”

Mr. Nick Chen, Partner of CGPM, commented: “Given our continuous focus and track record in the healthcare sector in Asia, we are very excited about our partnership with JINXIN Healthcare. The fruit of the hard work of several generations over 67 years, JINXIN Healthcare has become a rare privately-owned healthcare company in China that is able to compete with the best local public hospitals and even take a leading position in the medical specialties it operates in. The country’s ongoing healthcare reform and urban consumption upgrade trend will drive more market demand growth. We believe JINXIN Healthcare is well positioned to capture this historic opportunity.”

Mr. Jeffrey Li, the Founder and CEO of GL Capital, indicated, “The cooperation with such outstanding enterprise like Jinxin Group has always been the investment philosophy of GL Capital. JINXIN Healthcare is a leading healthcare group in Southwest China, and has already built up its excellent brand reputation in the areas of maternity, psychiatry and other medical services. We believe that this transaction is only the beginning of the cooperative development for all parties, and GL Capital will, as always, provide value-added services to our invested companies and help promote the development of the healthcare industry in China.”

Looking into the future, the Group will continue to seize opportunities in key markets, deepen the strategic layout of globalization and increase its international competitiveness, thereby accelerating corporate development and strengthening its three pillar businesses for the creation of greater value for its consumers and stakeholders.

About Chengdu Jinxin Healthcare Investment Management Group
Chengdu Jinxin Healthcare Investment Management Group, the predecessor of which was established in 1951, is renowned for its three pillar businesses of maternity and psychiatry services, in-vitro fertility (IVF) services and elderly care. After 67 years of development, the Group has become one of the leading private healthcare groups in China. The Group is also one of the first batch of healthcare institutions in Sichuan Province approved by National Health Ministry to carry out the human assisted reproductive technology. In terms of the number of IVF cycles, the Group is amid top five in China and ranks first among private providers. Since 2016, high-quality strategic investors including Warburg Pincus and Goldstone Haorui Investment under CITIC Securities have been successively introduced into its IVF segment.

About Capital Group Private Markets
Capital Group Private Markets (CGPM) is part of Capital Group, one of the world’s most successful investment institutions founded in 1931, and manages approximately US$1.7 trillion in assets. Over the last two decades, CGPM has invested over US$2 billion in emerging markets in Asia through its private equity funds. CGPM partners in particular with leading companies in the healthcare, consumer and business services sectors, including those with disruptive and/or technology-enabled business models.

About GL Capital
Established in 2010, GL Capital is a leading Greater China healthcare-focused, value-driven investment management group. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies.

Topic: Press release summary
Sectors: Daily FinanceDaily NewsHealthCare
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.